Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 12/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12746073 | 1.00 | CTSA (0.51) | CTSALMNAHPGDALOX15TSHR | |
| SCHEMBL12879472 | 0.84 | CTSA (0.47) | CTSA | |
| SCHEMBL2093768 | 0.78 | AOC3 (0.59) | TSHRMAPK1BRD4AOC3PKM | |
| SCHEMBL12746075 | 0.75 | LMNA (0.71) | CTSALMNAHPGDALOX15TSHR | |
| SCHEMBL1171873 | 0.75 | LMNA (0.71) | CTSALMNAHPGDALOX15TSHR | |
| SCHEMBL477338 | 0.73 | AOC3 (0.54) | BRD4AOC3PKML3MBTL1 | |
| SCHEMBL4822561 | 0.73 | AOC3 (0.54) | TSHRMAPK1BRD4AOC3PKM | |
| SCHEMBL27686957 | 0.73 | AOC3 (0.54) | BRD4AOC3PKML3MBTL1 | |
| SCHEMBL23882846 | 0.71 | ROCK1 (0.50) | MAPK1BRD4AOC3PKML3MBTL1 | |
| SCHEMBL23882848 | 0.71 | ROCK1 (0.50) | MAPK1BRD4AOC3PKML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102622-B2 | Fatty acid amide hydrolase inhibitors | UNIVERSITY OF CONNECTICUT (US) | 2015-08-11 | — | — | US | disclosed |
| US-20110071178-A1 | Methods and Compounds for Modulating Cannabinoid Activity | NORTHEASTERN UNIVERSITY (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110039874-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2011-02-17 | — | — | US | disclosed |
| US-20100234379-A1 | Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity | CONNECTICUT, UNIVERSITY OF | 2010-09-16 | — | — | US | disclosed |
| EP-2203412-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20090306016-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | UNIVERSITY OF CONNECTICUT | 2009-12-10 | — | — | US | disclosed |
| EP-2051964-A2 | FATTY ACID AMIDE HYDROLASE INHIBITORS | University of Connecticut (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2009052319-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2008013963-A2 | FATTY ACID AMIDE HYDROLASE INHIBITORS | UNIVERSITY OF CONNECTICUT (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039874-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | MGLL, FAAH, FAAH2 | CTSA 268/4885LMNA 2518/4885HPGD 952/4885 |
| US-20090306016-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | FAAH, FAAH2, CNR2 | CTSA 380/4885LMNA 4375/4885HPGD 524/4885 |
| US-20100234379-A1 | Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity | FAAH, FAAH2, CNR2 | CTSA 37/4885LMNA 3975/4885HPGD 1848/4885 |
| US-20110071178-A1 | Methods and Compounds for Modulating Cannabinoid Activity | FAAH, FAAH2, CNR2 | CTSA 573/4885LMNA 2779/4885HPGD 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.